Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo
The response rate in GSS to the drug was 27 / 148 (18.2%) in comparison to placebo with 7 / 150 (4.67%) Post-hoc analysis revealed no significant differences in efficacy between the gender and different age groups.

Related Post